WINT News and Press, Windtree Therapeutics Inc. From 03/22/21

Windtree Extends Scientific Collaboration in Heart Failure Studying Its SERCA2a Activators with the University of Milan-Bicocca Collaboration to focus on the continued development of chronic heart failure treatment SERCA2a activator compounds adding to Windtree's acute treatment...

Windtree to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire WARRINGTON, Pa. , March 8, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late...

Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceutica...

NanoViricides (NNVC) +112% on effectiveness of COVID-19 drug candidates in cell culture studies.Communications Systems (JCS) +38% after entering merger agreement with Pineapple Energy.STRATA Skin Sciences (SSKN) +30% on announcing CEO Transition.CHF Solutions (CHFS) +25%.AgeX T...

Windtree Announces Issuance of New U.S. Patent Covering Technology on Its Redesigned AEROSURF® Device New patent covers updated aerosol delivery system and design until 2039 PR Newswire WARRINGTON, Pa. , Feb. 16, 2021 /PRNewswire/ -- Windtree Therapeutic...

Windtree Strengthens Its Board by Appointing Three New Directors Company welcomes Dr. Evan Loh, Ms. Leslie Williams and Dr. Rob Scott, seasoned executives with deep cardiovascular development and commercial experience PR Newswire WARRINGTON, Pa. , Feb. 4, 2021 ...

Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development PR Newswire WARRINGTON, Pa. , Feb. 1, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-...

Biotechnology and medical device company Windtree Therapeutics (WINT) has dosed the first patient in its Phase 2 trial studying lucinactant in acute lung injury in adults with COVID-19 associated lung injury and acute respiratory distress syndrome ((ARDS)).Lucinactant is a synthetic KL4 surfa...

Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 The Phase 2 study will evaluate key physiological measures and is expected to be completed in 3-6 months PR Newswire WARRINGTON...

Windtree Therapeutics (WINT): Q3 GAAP EPS of -$0.54.Press Release For further details see: Windtree Therapeutics reports Q3 results